TRCT
DSGN icon

Tower Research Capital (TRC)’s Design Therapeutics DSGN Stock Holding History

Tower Research Capital (TRC)’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.4K Sell
1,545
-2,728
-64% -$27.6K ﹤0.01% 3614
2025
Q4 		$40.1K Buy
4,273
+2,314
+118% +$18.1K ﹤0.01% 2594
2025
Q3 		$14.8K Sell
1,959
-7,739
-80% -$38.8K ﹤0.01% 3574
2025
Q2 		$32.7K Buy
9,698
+1,796
+23% +$6.72K ﹤0.01% 3335
2025
Q1 		$30.5K Buy
7,902
+6,141
+349% +$29.3K ﹤0.01% 2596
2024
Q4 		$10.9K Buy
1,761
+56
+3% +$324 ﹤0.01% 3770
2024
Q3 		$9.17K Sell
1,705
-4,337
-72% -$20.4K ﹤0.01% 3896
2024
Q2 		$20.2K Buy
6,042
+3,365
+126% +$13.1K ﹤0.01% 3760
2024
Q1 		$10.8K Sell
2,677
-18,826
-88% -$50.3K ﹤0.01% 3650
2023
Q4 		$57K Buy
21,503
+4,983
+30% +$11.4K ﹤0.01% 3044
2023
Q3 		$39K Buy
16,520
+11,220
+212% +$52.3K ﹤0.01% 2769
2023
Q2 		$33.4K Buy
5,300
+3,201
+153% +$19.6K ﹤0.01% 2929
2023
Q1 		$12K Sell
2,099
-1,142
-35% -$8.54K ﹤0.01% 4067
2022
Q4 		$33K Sell
3,241
-5,769
-64% -$78.2K ﹤0.01% 2657
2022
Q3 		$151K Buy
9,010
+2,951
+49% +$58.7K ﹤0.01% 2185
2022
Q2 		$85K Buy
6,059
+5,669
+1,454% +$76.6K ﹤0.01% 2414
2022
Q1 		$6K Sell
390
-881
-69% -$13.5K ﹤0.01% 4868
2021
Q4 		$27K Buy
1,271
+825
+185% +$14.2K ﹤0.01% 3338
2021
Q3 		$7K Sell
446
-1,683
-79% -$28K ﹤0.01% 4632
2021
Q2 		$42K Buy
2,129
+1,731
+435% +$43.7K ﹤0.01% 3168
2021
Q1 		$12K Buy
+398
New +$13.4K ﹤0.01% 4250

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s DSGN Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Design Therapeutics (DSGN) stake by 64% in Q1 2026, selling an estimated $27.6K and leaving 1,545 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3614.

Tower Research Capital (TRC) first reported a position in DSGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $151K in Q3 2022. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Tower Research Capital (TRC) held 1,545 shares of Design Therapeutics worth $16.4K as of Q1 2026.
  • Tower Research Capital (TRC) sold 2,728 Design Therapeutics shares in Q1 2026, an estimated $27.6K.
  • Design Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3614 holding.
  • Tower Research Capital (TRC) first reported a position in Design Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Design Therapeutics position peaked at $151K in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.